How to Get BPC-157: Your Options in 2026
BPC-157 is not yet FDA approved. Here's a clear breakdown of your legitimate options, what's coming, and what to watch out for.
Research chemical in the US. Not FDA approved. No schedule classification. Legal gray area — legal to purchase for research, not for human use.
Option 1: Join a Clinical Trial
The only way to access BPC-157 through an official, regulated channel right now is to enroll in an active clinical trial. Eli Lilly is running Phase 3 TRIUMPH trials for Retatrutide across multiple sites in the US and internationally.
- •BMI ≥ 30, or ≥ 27 with at least one weight-related condition (hypertension, dyslipidemia, etc.)
- •No current or recent use of GLP-1 receptor agonists (semaglutide, tirzepatide, etc.)
- •No personal or family history of medullary thyroid carcinoma or MEN2
- •No active pancreatitis or severe GI conditions
- •Willing to attend regular in-person study visits
Option 2: Research Peptide Suppliers
A number of US-based peptide research suppliers offer BPC-157 as a research chemical. Quality varies significantly. If you are a researcher evaluating these sources, key quality indicators include:
Option 3: Compounding Pharmacies (Not Currently Available)
Unlike semaglutide and tirzepatide — which became available through compounding pharmacies during drug shortages — BPC-157 cannot legally be compounded. Compounding pharmacies can only compound drugs with an FDA-approved reference product, and BPC-157 has none yet.
What to Expect When BPC-157 Is Approved
Based on Eli Lilly's projected FDA filing in 2026–2027, here's what access will likely look like post-approval:
Alternatives Available Now
If you can't wait for BPC-157 approval, the currently available options with strong clinical backing are:
| Drug | Type | Avg Weight Loss | Status |
|---|---|---|---|
| Tirzepatide (Zepbound) | GIP/GLP-1 dual agonist | ~20–22% | FDA Approved |
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% | FDA Approved |
| Retatrutide | GIP/GLP-1/Glucagon triple | ~24% | Phase 3 Trials |
Frequently Asked Questions
How can I get BPC-157 right now?
BPC-157 is not yet FDA approved. The primary ways to access it are through clinical trials, or as a research chemical from verified peptide suppliers (not for human use).
Is BPC-157 available without a prescription?
BPC-157 is investigational and not available via prescription anywhere. Research-grade versions exist but are sold strictly for laboratory or research use — not for human consumption.
Can I join a BPC-157 clinical trial?
Yes. Eli Lilly is running Phase 3 TRIUMPH trials for Retatrutide. You can search active trials at ClinicalTrials.gov using the identifier NCT05703841 or by searching "retatrutide." Trials typically require BMI ≥ 30 (or ≥ 27 with a weight-related condition) and no recent GLP-1 use.
When will BPC-157 be available to the general public?
Based on current Phase 3 timelines and Eli Lilly's projected FDA filing in 2026–2027, BPC-157 could be available via prescription by 2027–2028 if approved on schedule.
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.